title: Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
abstract: BACKGROUND
  Therapeutic antibodies targeting the IGF1R have shown diverse efficacy and safety signals in oncology clinical trials. The success of these agents as future human therapeutics depends on understanding the specific mechanisms by which these antibodies target IGF1R signaling.
  
  
  RESULTS
  A panel of well-characterized assays was used to investigate the mechanisms by which ganitumab, a fully human anti-IGF1R antibody undergoing clinical testing, inhibits IGF1R activity. Epitope mapping using IGF1R subdomains localized the ganitumab binding site to the L2 domain. Binding of ganitumab inhibited the high-affinity interaction of IGF-1 and IGF-2 required to activate IGF1R in cells engineered for IGF1R hypersensitivity and in human cancer cell lines, resulting in complete blockade of ligand-induced cellular proliferation. Inhibition of IGF1R activity by ganitumab did not depend on endosomal sequestration, since efficient ligand blockade was obtained without evidence of receptor internalization and degradation. Clinically relevant concentrations of ganitumab also inhibited the activation of hybrid receptors by IGF-1 and IGF-2. Ganitumab was not an agonist of homodimeric IGF1R or hybrid receptors in MCF-7 and COLO 205 cells, but low-level IGF1R activation was detected in cells engineered for IGF1R hypersensitivity. This activation seems biologically irrelevant since ganitumab completely inhibited ligand-driven proliferation. The in vivo efficacy profile of ganitumab was equivalent or better than CR and FnIII-1 domain-specific antibodies, alone or in combination with irinotecan. CR domain-specific antibodies only blocked IGF-1 binding to IGF1R but were more potent than ganitumab at inducing homodimer and hybrid receptor downregulation in vitro, however this difference was less obvious in vivo. No inhibition of hybrid receptors was observed with the FnIII-1 domain antibodies, which were relatively strong homodimer and hybrid agonists.
  
  
  CONCLUSIONS
  The safety and efficacy profile of ganitumab and other anti-IGF1R antibodies may be explained by the distinct molecular mechanisms by which they inhibit receptor signaling.
authors: Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America.
authors: Frank J
authors: FJ
authors: Calzone
authors: Elaina
authors: E
authors: Cajulis
authors: Young-Ah
authors: YA
authors: Chung
authors: Mei-Mei
authors: MM
authors: Tsai
authors: Petia
authors: P
authors: Mitchell
authors: John
authors: J
authors: Lu
authors: Ching
authors: C
authors: Chen
authors: Jilin
authors: J
authors: Sun
authors: Robert
authors: R
authors: Radinsky
authors: Richard
authors: R
authors: Kendall
authors: Pedro J
authors: PJ
authors: Beltran
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000915:Antibody Affinity; D001665:Binding Sites / Q000235:genetics; D049109:Cell Proliferation; D018604:Epitope Mapping; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D061986:MCF-7 Cells; D051379:Mice; D008819:Mice, Nude; D010766:Phosphorylation; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; C545764:ganitumab; D017526:Receptor, IGF Type 1
references: J Clin Oncol. 2009 Dec 1;27(34):5800-7
references: 19786654
references: Clin Cancer Res. 2005 Mar 1;11(5):2063-73
references: 15756033
references: Clin Cancer Res. 2012 Jun 15;18(12):3414-27
references: 22510349
references: Trends Biochem Sci. 2008 Aug;33(8):376-84
references: 18640841
references: Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):54-72
references: 19149688
references: Nat Rev Cancer. 2012 Feb 16;12(3):159-69
references: 22337149
references: J Pharmacol Exp Ther. 2011 Jun;337(3):644-54
references: 21385891
references: Mol Cell Biol. 1999 Oct;19(10):7203-15
references: 10490655
references: Clin Cancer Res. 1999 Jul;5(7):1935-44
references: 10430101
references: Oncogene. 2009 Aug 27;28(34):3009-21
references: 19581933
references: Mol Cancer Ther. 2008 Jul;7(7):2233-40
references: 18645032
references: Cancer Res. 2005 Dec 15;65(24):11236-40
references: 16357124
references: Cell Mol Life Sci. 2000 Jul;57(7):1050-93
references: 10961344
references: Cell Cycle. 2012 Apr 1;11(7):1455-67
references: 22421160
references: Nat Rev Drug Discov. 2002 Oct;1(10):769-83
references: 12360255
references: Biochem Biophys Res Commun. 1990 Sep 28;171(3):1244-51
references: 2171510
references: Endocr Rev. 2009 Oct;30(6):586-623
references: 19752219
references: J Biol Chem. 2009 Apr 10;284(15):10254-67
references: 19211557
references: PLoS One. 2012;7(3):e33581
references: 22479414
references: J Biol Chem. 1992 Jun 25;267(18):12955-63
references: 1377676
references: Endocrinology. 2011 Jul;152(7):2546-51
references: 21540285
references: J Biol Chem. 1983 May 25;258(10):6561-6
references: 6304046
references: Horm Res. 2001;55 Suppl 2:22-6
references: 11684871
references: Trends Endocrinol Metab. 2010 Oct;21(10):610-8
references: 20663687
references: Mol Cancer Ther. 2002 Dec;1(14):1349-53
references: 12516969
references: Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5356-60
references: 1319060
references: J Mol Endocrinol. 2011 Jun 17;47(1):R1-10
references: 21498522
references: PLoS One. 2011;6(5):e19846
references: 21611203
references: Mol Cancer Ther. 2009 May;8(5):1095-105
references: 19366899
references: J Natl Cancer Inst. 2012 Jul 3;104(13):975-81
references: 22761272